A Double-blind, Randomized, Placebo-controlled, Multi-center Study Evaluating the Safety, Tolerability, and Effect of Olpasiran on Coronary Artery Plaque Burden Assessed by Coronary Computed Tomography Angiography in Participants With Stable Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a)

Status

Not yet recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521117-88-00

Acronym

20230191

Enrollment

178

Registered

2025-12-22

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease

Brief summary

change in non-calcified plaque volume from baseline to week 72

Detailed description

change in the following volume types from baseline to week 72: -low attenuation plaque volume -total plaque volume -calcified plaque volume

Interventions

DRUGPlacebo for AMG 890

DRUGOlpasiran

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
change in non-calcified plaque volume from baseline to week 72	—

Secondary

Measure	Time frame
change in the following volume types from baseline to week 72: -low attenuation plaque volume -total plaque volume -calcified plaque volume	—

Countries

Denmark, France, Germany, Italy, Netherlands, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026